

# Serum Prolactin and Macroprolactin Levels among Outpatients with Major Depressive Disorder Following the Administration of Selective Serotonin-Reuptake Inhibitors: A Cross-Sectional Pilot Study

Sollip Kim<sup>1</sup>, Young-Min Park<sup>2\*</sup>

**1** Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea, **2** Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea

## Abstract

Clinical trials evaluating the rate of short-term selective serotonin-reuptake inhibitor (SSRI)-induced hyperprolactinemia have produced conflicting results. Thus, the aim of this study was to clarify whether SSRI therapy can induce hyperprolactinemia and macroprolactinemia. Fifty-five patients with major depressive disorder (MDD) were enrolled in this study. Serum prolactin and macroprolactin levels were measured at a single time point (i.e., in a cross-sectional design). All patients had received SSRI monotherapy (escitalopram, paroxetine, or sertraline) for a mean of 14.75 months. Their mean prolactin level was 15.26 ng/ml. The prevalence of patients with hyperprolactinemia was 10.9% for 6/55, while that of patients with macroprolactinemia was 3.6% for 2/55. The mean prolactin levels were 51.36 and 10.84 ng/ml among those with hyperprolactinemia and a normal prolactin level, respectively. The prolactin level and prevalence of hyperprolactinemia did not differ significantly within each SSRI group. Correlation analysis revealed that there was no correlation between the dosage of each SSRI and prolactin level. These findings suggest that SSRI therapy can induce hyperprolactinemia in patients with MDD. Clinicians should measure and monitor serum prolactin levels, even when both SSRIs and antipsychotics are administered.

**Citation:** Kim S, Park Y-M (2013) Serum Prolactin and Macroprolactin Levels among Outpatients with Major Depressive Disorder Following the Administration of Selective Serotonin-Reuptake Inhibitors: A Cross-Sectional Pilot Study. PLoS ONE 8(12): e82749. doi:10.1371/journal.pone.0082749

**Editor:** Lucio Annunziato, University of Naples Federico II, Italy

**Received May 24, 2013; Accepted October 28, 2013; Published December 2, 2013**

**Copyright:** © 2013 Kim, Park. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by the 2012 Inje University research grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

\* E-mail: medipark@hanmail.net

## Introduction

There is evidence that selective serotonin-reuptake inhibitors (SSRIs) can induce hyperprolactinemia, which causes galactorrhea, gynecomastia, hormonal abnormality, and sexual dysfunction [1,2]. Even Cohen and Davies reported that SSRIs were most frequent cause of drug-induced hyperprolactinemia [3]. However, most of clinical trials designed to evaluate prospectively the rate of short-term (1 day–12 weeks) SSRI-induced hyperprolactinemia have produced conflicting results [4], with some studies showing that SSRIs can increase the level of serum prolactin (PRL) [5–8], while others demonstrating no such increase [9–13]. Papakostas and colleagues recently reported that 4.5% of men and 22.2% of women with major depressive disorder (MDD) developed new-onset hyperprolactinemia following treatment with fluoxetine [14]. Macroprolactin essentially comprises a complex of PRL with immunoglobulin G (IgG), especially anti-PRL

autoantibodies [15]. In addition, macroprolactinemia is a heterogeneous state with various causes, with 87% of macroprolactin comprising PRL-IgG complex and 67% being autoantibody-bound PRL [15,16]. However, macroprolactin does not seem to induce hyperprolactinemia-related adverse effects due to its low bioactivity.

Most of these previous prolactin studies analyzed the condition of patients with short-duration SSRI therapy. The purpose of this study was to clarify whether relatively long-term SSRI therapy can induce hyperprolactinemia. Both PRL and macroprolactin levels were measured, the latter because it is clinically important in that it has low bioactivity. To our knowledge this is the first study to examine macroprolactin levels in patients with MDD who received SSRI therapy.

## Materials

### Subjects

In total, 55 outpatients who met the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) for MDD were enrolled in this study. The subjects, who had been receiving long-term (mean, 14.75 months) SSRI medication, were recruited from an outpatient clinic. They had not been diagnosed with any major mental disorders on axis I or axis II of the DSM-IV (including schizophrenia, bipolar disorder, anxiety disorder, eating disorder, or borderline personality disorder) or major medical and/or neurological disorders. Patients taking psychotropic agents other than hypnotic drugs (benzodiazepine or zolpidem) and SSRIs including escitalopram, paroxetine, or sertraline were excluded. The study was conducted from January 2012 to April 2013. Written informed consent to participate was obtained from all patients before beginning the investigation, and the applied protocol was approved by the institutional review board of Inje University.

### Study design

Serum PRL and macroprolactin levels were measured at a single time point (i.e., in a cross-sectional design). All patients had received SSRI monotherapy including escitalopram ( $n=35$ ), paroxetine ( $n=24$ ), or sertraline ( $n=6$ ) for a mean of 14.75 (range, 2–84) months. A blood sample was taken from each subject in the morning in a fasting state (91%, 50/55). The normal range of PRL levels reported in the hospital laboratory is 4.0–15.2 ng/ml in men and 4.8–23.3 ng/ml in women.

### Measurements of PRL and macroprolactin

Macroprolactinemia screening was performed as described previously [17]. Serum samples were precipitated with polyethylene glycol (PEG; PEG 8000, Sigma-Aldrich, St. Louis, MO, USA) and the supernatants were assayed for PRL using Roche PRL assays (Roche Diagnostics, Indianapolis, IN, USA). The results were compared with those of direct serum PRL assays. The PRL concentration in the supernatant after PEG treatment was defined as free PRL, and the concentration without PEG treatment was defined as total PRL. The PEG-precipitated PRL was calculated as a percentage using the following equation: (total PRL-free PRL)/total PRL×100. A value greater than 52.8% [corresponding to the mean plus two standard deviations (SDs)] defined macroprolactinemia in this study. The concentration of PRL was measured using an automated chemiluminescence assay (Roche Diagnostics).

### Analysis

All statistical analyses were carried out using the SAS 9.3 software package and SALT 2.5, and all results are reported as mean $\pm$ SD values. The demographic and clinical variables, PRL levels, and frequencies of some group variables were compared using Student's *t* test, ANOVA, the chi-square test, and correlation analysis (Pearson's correlation). Student's *t* test was used to determine the mean and SD values, and whether there were significant differences between groups with respect

**Table 1.** Demographic and clinical variables in normal prolactin group and hyperprolactinemia group.

Variables	Normal PRL group (n=49)	Hyperprolactinemia group (n=6)	p-value
Age (years)	48.43 $\pm$ 17.19	45.0 $\pm$ 23.26	0.66
Sex (M/F)*	11/38	2/4	0.62
Treatment duration (months)	14.29 $\pm$ 18.41	18.83 $\pm$ 16.56	0.57
HAMD	6.27 $\pm$ 5.33	9.33 $\pm$ 6.09	0.19
PRL level before PEG (ng/ml)	10.84 $\pm$ 4.71	51.36 $\pm$ 55.08	0.0000019**
PRL level after PEG (ng/ml)	8.47 $\pm$ 3.80	34.35 $\pm$ 28.05	0.00000041**
PEG-precipitated PRL (%)	23.99 $\pm$ 11.93	24.44 $\pm$ 9.81	0.93
Macroprolactinemia (yes/no)	2/47	0/6	N/A

\* Fisher's Exact Test, \*\* P<0.05, PRL; prolactin, N/A; nonavailable


doi: 10.1371/journal.pone.0082749.t001

to age, PRL level, macroprolactin level, and treatment duration of SSRIs. ANOVA and the Tukey post-hoc test were used to determine the PRL and macroprolactin levels relative to each SSRI, and the chi-square test was used to determine whether the difference among groups was significant with respect to the frequency of hyperprolactinemia according to each antidepressant. Correlation analysis using Pearson's correlation was carried out to establish clearly whether there was any significant correlation between the treatment duration of each SSRI and PRL level. All tests were two tailed, and group differences were considered to be significant when p<0.05.

## Results

The mean PRL level before PEG and the free PRL level after PEG in our sample of 55 patients with MDD were 15.26 and 11.29 ng/ml, respectively, and the mean SSRI treatment duration for the current episode was 14.75 months. The prevalence rates of patients with hyperprolactinemia and macroprolactinemia were 10.9% for 6/55 and 3.6% for 2/55, respectively (Table 1). The PRL level did not differ significantly between males (14.41 $\pm$ 8.74 ng/ml) and females (15.52 $\pm$ 24.24 ng/ml, p=0.87) (Table 2). Two male and four female patients presented with hyperprolactinemia. However, none of the patients with hyperprolactinemia also had macroprolactinemia; all of the patients with macroprolactinemia ( $n=2$ ) had PRL levels within the normal range, even before PEG treatment (Table 1). The PRL level did not differ between patients who had received SSRI monotherapy for at least 6 months ( $n=34$ ) and for less than 6 months ( $n=21$ ), respectively.

The mean PRL levels were 51.36 and 10.84 ng/ml among those with hyperprolactinemia and normal PRL levels, respectively (Table 1). The mean PRL levels before PEG treatment among those taking escitalopram, paroxetine, and sertraline were 13.25, 21.62, and 12.15 ng/ml, respectively; the



**Figure 1.** Mean prolactin levels before PEG among patients taking escitalopram, paroxetine, and sertraline (ESC; escitalopram, PRX; paroxetine, SERT; sertraline).

doi: 10.1371/journal.pone.0082749.g001

**Table 2.** Demographic and clinical variables between male and female groups.

Variables	Male (n=13)	Female (n=42)	p-value
Age (years)	41.38±18.21	50.12±17.26	0.12
Treatment duration (months)	8.31±8.98	16.79±19.80	0.14
PRL level before PEG (ng/ml)	14.41±8.73	15.52±24.23	0.87
PRL level after PEG (ng/ml)	10.87±7.12	11.42±13.61	0.89
PEG-precipitated PRL (%)	25.33±11.26	23.64±11.86	0.65
Macroprolactinemia (yes/no)*	1/13	1/42	0.42

\* Fisher's Exact Test, PRL; prolactin

doi: 10.1371/journal.pone.0082749.t002

mean free prolactin levels after PEG treatment were 10.34, 14.37, and 9.64 ng/ml, respectively (Table 3). There was no statistically significant difference among each SSRI group with respect to mean PRL level before PEG treatment or mean free PRL level after PEG treatment (Figure 1, 2, and Table 3). In addition, there was no statistically significant difference between pairs of SSRI groups in prolactin levels (escitalopram vs paroxetine, paroxetine vs sertraline, and escitalopram vs sertraline) (Tukey post-hoc analysis,  $p>0.05$ ). The frequency of patients with hyperprolactinemia also did not differ within each SSRI group (Table 3). Correlation analysis revealed no correlation between the treatment duration or dosage of each SSRI and PRL level (Figure 3, Figure 4).

**Table 3.** Comparison of prolactin levels and the frequency of subjects with hyperprolactinemia among each SSRI group.

Variables	ESC	PRX	SERT	p-value
PRL level before PEG (ng/ml)	13.25±7.23	21.62±41.17	12.15±9.29	0.45
PRL level after PEG (ng/ml)	10.34±5.75	14.37±22.60	9.64±7.25	0.56
Hyperprolactinemia (yes/no)*	3/32	2/12	1/5	0.53

PRL; prolactin, ESC:escitalopram, PRX:paroxetine, SERT; sertraline,


\* Fisher's Exact Test

doi: 10.1371/journal.pone.0082749.t003

## Discussion


The results presented herein revealed that the prevalence of SSRI-induced hyperprolactinemia was 10.9%. This value is similar to that of 12.5% found by Papakostas and colleagues in a cohort with hyperprolactinemia induced following 12 weeks of fluoxetine [14]. In addition, Pearson's correlation revealed no significant correlation between the SSRI treatment duration and PRL level in the present study ( $r=0.229$ ,  $p=0.093$ ). Thus, it seems that the treatment duration of SSRIs does not have a major impact on hyperprolactinemia.

Some studies, including the present one, have shown that SSRIs can increase the serum level of PRL [5–8], and yet others have found no such increase in serum PRL [9–13]. Thus, the findings of SSRI-induced hyperprolactinemia remain a matter of controversy. However, the mean PRL level was 28.93 ng/ml for five of the six patients with hyperprolactinemia




**Figure 2.** Mean prolactin levels after PEG among patients taking escitalopram, paroxetine, and sertraline (ESC; escitalopram, PRX; paroxetine, SERT; sertraline).

doi: 10.1371/journal.pone.0082749.g002



**Figure 3.** Correlation between the treatment duration of each SSRI and prolactin levels.

doi: 10.1371/journal.pone.0082749.g003



duration of SSRIs was 14.75 months, in contrast to the previous, shorter-term studies (range, 1 day-12 weeks). In addition, this is the first study to examine macroprolactin levels in patients with MDD who received SSRI therapy. Furthermore, all of the patients are Korean and outpatients with MDD, and so the sample was relatively homogeneous.

The present findings suggest that SSRI therapy can induce hyperprolactinemia in patients with MDD. Clinicians should measure and monitor serum PRL levels in these patients, even when they are receiving both SSRIs and antipsychotics.

## References

1. Torre DL, Falorni A (2007) Pharmacological causes of hyperprolactinemia. *Ther Clin Risk Manag* 3: 929-951.
2. Emiliano AB, Fudge JL (2004) From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. *Neuropsychopharmacology* 29: 833-846. doi:10.1038/sj.npp.1300412. PubMed: 14997175.
3. Cohen M, Davies P (1998) Drug therapy and hyperprolactinaemia. *Adv Drug Reaction Bull* 190: 723-726.
4. Molitch ME (2008) Drugs and prolactin. *Pituitary* 11: 209-218. doi: 10.1007/s11102-008-0106-6. PubMed: 18404390.
5. Spigset O, Mjordal T (1997) The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. *J Clin Psychopharmacol* 17: 292-297. doi: 10.1097/00004714-199708000-00009. PubMed: 9241009.
6. Urban RJ, Veldhuis JD (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. *Am J Obstet Gynecol* 164: 147-152. doi: 10.1016/0002-9378(91)90645-8. PubMed: 1986602.
7. Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R et al. (1997) Lack of adverse interactions between concomitantly administered selegiline and citalopram. *Clin Neuropharmacol* 20: 419-433. doi: 10.1097/00002826-199710000-00006. PubMed: 9331518.
8. Amsterdam JD, Garcia-España F, Goodman D, Hooper M, Hornig-Rohan M (1997) Breast enlargement during chronic antidepressant therapy. *J Affect Disord* 46: 151-156. doi:10.1016/S0165-0327(97)00086-4. PubMed: 9479619.
9. Salzman C, Jimerson D, Vasile R, Watsky E, Gerber J (1993) Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study. *Biol Psychiatry* 34: 569-571. doi: 10.1016/0006-3223(93)90202-O. PubMed: 8274586.
10. Mück-Seler D, Pivac N, Sagud M, Jakovljević M, Mihajlović-Peles A (2002) The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 26: 1235-1243. doi:10.1016/S0278-5846(02)00259-2. PubMed: 12502009.
11. Sagud M, Pivac N, Mück-Seler D, Jakovljević M, Mihajlović-Peles A et al. (2002) Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. *Neuropsychobiology* 45: 139-143. doi:10.1159/000054954. PubMed: 11979064.
12. Schlosser R, Wetzel H, Dör H, Rossbach W, Hiemke C et al. (2000) Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. *Psychoneuroendocrinology* 25: 377-388. doi:10.1016/S0306-4530(99)00065-7. PubMed: 10725614.
13. Shilik J, Aluoja A, Vasar V, Vasar E, Podar T et al. (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. *J Psychiatry Neurosci* 22: 332-340. PubMed: 9401314.
14. Papakostas GI, Miller KK, Petersen T, Sklar斯基 KG, Hilliker SE et al. (2006) Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. *J Clin Psychiatry* 67: 952-957. doi:10.4088/JCP.v67n0612. PubMed: 16848655.
15. Shimatsu A, Hattori N (2012) Macroprolactinemia: diagnostic, clinical, and pathogenic significance. *Clin Dev Immunol* 2012: 167132.
16. Hattori N, Ishihara T, Saiki Y, Shimatsu A (2010) Macroprolactinemia in patients with hyperprolactinemia: composition of macroprolactin and stability during long-term follow-up. *Clin Endocrinol (Oxf)* 73: 792-797. doi:10.1111/j.1365-2265.2010.03880.x. PubMed: 20874771.
17. Olukoga AO, Kane JW (1999) Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. *Clin Endocrinol (Oxf)* 51: 119-126. doi: 10.1046/j.1365-2265.1999.00757.x. PubMed: 10468974.
18. Coker F, Taylor D (2010) Antidepressant-induced hyperprolactinemia: incidence, mechanisms and management. *CNS Drugs* 24: 563-574. doi:10.2165/11533140-000000000-00000. PubMed: 20527996.
19. Hattori N, Adachi T, Ishihara T, Shimatsu A (2012) The natural history of macroprolactinemia. *Eur J Endocrinol* 166: 625-629. doi:10.1530/EJE-11-1007. PubMed: 22247016.
20. Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR et al. (2001) Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. *J Clin Endocrinol Metab* 86: 2743-2746. doi: 10.1210/jc.86.6.2743. PubMed: 11397880.
21. McKenna TJ (2009) Should macroprolactin be measured in all hyperprolactinemic sera? *Clin Endocrinol (Oxf)* 71: 466-469. doi: 10.1111/j.1365-2265.2009.03577.x. PubMed: 19320649.
22. Bjørø T, Mørkrid L, Wergeland R, Turter A, Kvistborg A et al. (1995) Frequency of hyperprolactinemia due to large molecular weight prolactin (150-170 kD PRL). *Scand J Clin Lab Invest* 55: 139-147. doi: 10.3109/00365159509089606. PubMed: 7667607.
23. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S et al. (2002) Macroprolactinemia revisited: a study on 106 patients. *J Clin Endocrinol Metab* 87: 581-588. doi:10.1210/jc.87.2.581. PubMed: 11836289.
24. Gibney J, Smith TP, McKenna TJ (2005) The impact on clinical practice of routine screening for macroprolactin. *J Clin Endocrinol Metab* 90: 3927-3932. doi:10.1210/jc.2004-2234. PubMed: 15811931.
25. Gibney J, Smith TP, McKenna TJ (2005) Clinical relevance of macroprolactin. *Clin Endocrinol (Oxf)* 62: 633-643. doi:10.1111/j.1365-2265.2005.02243.x. PubMed: 15943822.
26. Hauache OM, Rocha AJ, Maia AC Jr., Maciel RM, Vieira JG (2002) Screening for macroprolactinemia and pituitary imaging studies. *Clin Endocrinol (Oxf)* 57: 327-331. doi:10.1046/j.1365-2265.2002.01586.x. PubMed: 12201824.
27. Hattori N, Ishihara T, Saiki Y (2009) Macroprolactinemia: prevalence and aetiologies in a large group of hospital workers. *Clin Endocrinol (Oxf)* 71: 702-708. doi:10.1111/j.1365-2265.2009.03570.x.
28. Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A et al. (2010) Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. *Eur J Pharmacol* 647: 90-96. doi:10.1016/j.ejphar.2010.08.026. PubMed: 20816814.
29. Richelson E (2003) Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. *J Clin Psychiatry* 64 Suppl 13: 5-12. doi:10.4088/JCP.v64n0301. PubMed: 14552650.
30. Lee BH, Kang SG, Kim TW, Lee HJ, Yoon HK et al. (2012) Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. *Psychiatry Clin Neurosci* 66: 69-73. doi:10.1111/j.1440-1819.2011.02296.x. PubMed: 22250612.
31. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP et al. (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. *J Clin Psychiatry* 65: 57-61. doi:10.4088/JCP.v65n0109. PubMed: 14744169.
32. Karaganian JL, Baksh A (2003) High-dose olanzapine and prolactin levels. *J Clin Psychiatry* 64: 1192-1194. doi:10.4088/JCP.v64n1008. PubMed: 14658967.

## Acknowledgements

The authors thank T.H. Um, E.H. Joo, Y.J. Lee, and T.Y. Noh for their assistance with data collection.

## Author Contributions

Conceived and designed the experiments: SK YMP. Performed the experiments: SK YMP. Analyzed the data: YMP. Contributed reagents/materials/analysis tools: SK. Wrote the manuscript: SK YMP.

33. Stevens JR, Kymmissis PI, Baker AJ (2005) Elevated prolactin levels in male youths treated with risperidone and quetiapine. *J Child Adolesc Psychopharmacol* 15: 893-900. doi:10.1089/cap.2005.15.893. PubMed: 16379509.